CA2338638C - Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity - Google Patents

Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity Download PDF

Info

Publication number
CA2338638C
CA2338638C CA002338638A CA2338638A CA2338638C CA 2338638 C CA2338638 C CA 2338638C CA 002338638 A CA002338638 A CA 002338638A CA 2338638 A CA2338638 A CA 2338638A CA 2338638 C CA2338638 C CA 2338638C
Authority
CA
Canada
Prior art keywords
carnitine
taxol
acetyl
anticancer
alc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002338638A
Other languages
English (en)
French (fr)
Other versions
CA2338638A1 (en
Inventor
Claudio Cavazza
Claudio Pisano
Loredana Vesci
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT98RM000511 external-priority patent/IT1302121B1/it
Priority claimed from IT1999RM000206 external-priority patent/IT1306124B1/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CA2338638A1 publication Critical patent/CA2338638A1/en
Application granted granted Critical
Publication of CA2338638C publication Critical patent/CA2338638C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002338638A 1998-07-30 1999-07-27 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity Expired - Fee Related CA2338638C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IT98RM000511 IT1302121B1 (it) 1998-07-30 1998-07-30 Associazione ad attivita' antineoplastica sostanzialmente priva deglieffetti tossici o collaterali causati dai farmaci antineoplastici
ITRM98A000511 1998-07-30
IT1999RM000206 IT1306124B1 (it) 1999-04-07 1999-04-07 Uso di alcanoil l-carnitine nella preparazione di medicamenti adattivita' antitumorale.
ITRM99A000206 1999-04-07
PCT/IT1999/000242 WO2000006134A2 (en) 1998-07-30 1999-07-27 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity

Publications (2)

Publication Number Publication Date
CA2338638A1 CA2338638A1 (en) 2000-02-10
CA2338638C true CA2338638C (en) 2009-03-17

Family

ID=26332128

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002338638A Expired - Fee Related CA2338638C (en) 1998-07-30 1999-07-27 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity

Country Status (11)

Country Link
US (5) US6610699B2 (https=)
EP (1) EP1100589B1 (https=)
JP (2) JP4703851B2 (https=)
KR (1) KR100645980B1 (https=)
AT (1) ATE287278T1 (https=)
AU (1) AU764807B2 (https=)
CA (1) CA2338638C (https=)
DE (1) DE69923322T2 (https=)
ES (1) ES2235499T3 (https=)
PT (1) PT1100589E (https=)
WO (1) WO2000006134A2 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US20030199535A1 (en) * 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
IT1302289B1 (it) * 1998-09-30 2000-09-05 Univ Catania Composizioni farmaceutiche ad attivita' antineoplastica
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
DE19959546A1 (de) * 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
IL155273A0 (en) * 2000-10-12 2003-11-23 Pharma Mar Sa Pharmaceutical compositions comprising an aplidine compound
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
AU2004218883B2 (en) 2003-03-12 2009-10-01 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
US8314144B2 (en) * 2004-02-12 2012-11-20 Defiante Farmaceutica, S.A. Compounds having antitumor activity
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
ITMI20070817A1 (it) 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
US8613962B2 (en) * 2007-08-31 2013-12-24 Kyushu University, National University Corporation Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
JP2012510498A (ja) * 2008-12-01 2012-05-10 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ 新生物の処置のための化学療法剤との組み合わせにおけるアルカノイルｌ−カルニチンの使用
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ES2481865T3 (es) 2010-01-29 2014-07-31 Abbott Laboratories Emulsiones nutricionales que comprenden HMB de calcio
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
CA3291904A1 (en) 2012-06-27 2026-03-02 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
RU2554776C1 (ru) * 2013-12-16 2015-06-27 Федеральное государственное бюджетное учреждение "Дальневосточный научный центр физиологии и патологии дыхания" СО РАМН Средство для коррекции нарушений в легочной ткани при цитостатическом воздействии
HK1251655A1 (zh) 2015-04-20 2019-02-01 Tolero Pharmaceuticals, Inc. 通过线粒体分析预测对阿伏西地的应答
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
KR101732483B1 (ko) * 2016-07-06 2017-05-24 한국 한의학 연구원 연교 추출물을 유효성분으로 함유하는 말초신경병증 예방, 개선 또는 치료용 조성물
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
US4267163A (en) * 1972-11-06 1981-05-12 Biocarn Limited Carnitine and its use in reducing cardiac toxicity
IT1169460B (it) * 1982-09-13 1987-05-27 Sigma Tau Ind Farmaceuti Metodo e composizione per il trattamento di tumori
IL74449A (en) * 1984-03-01 1988-07-31 Us Commerce Tetrahalo-1,2-cyclohexane-diamino platinum complexes and anti-neoplastic compositions comprising them
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
US4936823A (en) * 1988-05-04 1990-06-26 Triangle Research And Development Corp. Transendoscopic implant capsule
IT1235153B (it) * 1988-11-15 1992-06-22 Sigma Tau Ind Farmaceuti Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
IT1275434B (it) * 1995-05-19 1997-08-07 Farmila Farma Milano Composizioni farmaceutiche e/o dietetiche ad attivita' antiossidante
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
DE19733305A1 (de) * 1997-08-01 1999-02-04 Asta Medica Ag Pharmazeutische Zusammensetzung enthaltend Ifosfamid und Carnitin

Also Published As

Publication number Publication date
US6610699B2 (en) 2003-08-26
JP2010254717A (ja) 2010-11-11
US20090143464A1 (en) 2009-06-04
CA2338638A1 (en) 2000-02-10
DE69923322D1 (de) 2005-02-24
EP1100589B1 (en) 2005-01-19
ES2235499T3 (es) 2005-07-01
KR20010072093A (ko) 2001-07-31
JP2002521428A (ja) 2002-07-16
HK1035677A1 (en) 2001-12-07
WO2000006134A3 (en) 2000-03-23
EP1100589A2 (en) 2001-05-23
PT1100589E (pt) 2005-05-31
ATE287278T1 (de) 2005-02-15
DE69923322T2 (de) 2005-12-22
AU5193599A (en) 2000-02-21
KR100645980B1 (ko) 2006-11-14
US20010044465A1 (en) 2001-11-22
US20080194683A1 (en) 2008-08-14
AU764807B2 (en) 2003-08-28
WO2000006134A2 (en) 2000-02-10
US20090137619A1 (en) 2009-05-28
JP4703851B2 (ja) 2011-06-15
US20060258744A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
CA2338638C (en) Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
DE69822659T2 (de) Formulierungen und Verfahren zur Verminderung der Toxizität von Anti-Neoplastischen Mitteln
AU2003286647B2 (en) Method and composition for preventing and treating solid tumors
JP2005008534A (ja) 抗癌剤及び癌の治療方法
DE68902581T2 (de) Pharmazeutische zusammensetzungen mit krebshemmender wirkung.
AU697742B2 (en) Treatment of cytokine growth factor caused disorders
US20060183798A1 (en) Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
CN116726021B (zh) 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途
US20060057237A1 (en) Extract with anti-tumor and anti-poisonous activity
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
WO2009052630A1 (en) Compositions and methods for treating fibroproliferative disorders
HK1035677B (en) Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity
JPH08509961A (ja) 低密度リポタンパク質および細胞毒性物質の使用
MXPA01001065A (es) Uso de l-carnitina y sus derivados alcanoilo en la preparacion de medicamentos con actividad contra el cancer
EP1441717B1 (en) Combination of an atp-competitive inhibitor of bcr/abl kinase activity and a tyrphostin analog
Dittrich et al. In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma
ITRM990206A1 (it) Uso di alcanoil l-carnitine nella preparazione di medicamenti ad attivita' antitumorale.
CN119318654A (zh) 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用
Molnár et al. Effect of lithium carbonate on the peripheral leukocyte count in children suffering from haematological malignancies
JPH01275531A (ja) 癌細胞転移抑制剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140729